What question did this study set out to answer?

To evaluate the efficacy and tolerability of cevimeline in relieving dry mouth and dry eyes in patients diagnosed with Sjögren's syndrome.

March 1, 2002Arthritis & Rheumatism

A double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and tolerability of cevimeline in relieving dry mouth and dry eyes in patients diagnosed with Sjögren's syndrome.
Conducted a double-blind, randomized, placebo-controlled trial.
Administered oral cevimeline at dosages of 15 mg or 30 mg three times daily versus placebo to patients with xerostomia and keratoconjunctivitis sicca.
Measured objective saliva and tear flow rates alongside self-reported assessments of mouth, eye, and global dryness.
Treatment with 30 mg of cevimeline three times daily substantially increased objective saliva and tear flow rates.
Patients receiving 30 mg experienced significant qualitative improvement in subjective symptoms of dry mouth, dry eyes, and overall dryness, while the 15-mg dosage provided partial symptom relief.
Both the 15-mg and 30-mg dosages were well tolerated across the study cohort.

Implication

Randomized double-blind trial demonstrates improved saliva and tear production from cevimeline in Sjögren's syndrome, indicating its efficacy for severe dryness.

Abstract

Treatment with cevimeline at a dosage of 30 mg 3 times daily resulted in substantive improvement by increasing the rate of saliva and tear flow in patients with Sjögren's syndrome, as well as improving subjective symptoms of dry mouth, dry eyes, and overall dryness. The 15-mg dosage relieved some symptoms, and both dosages were well tolerated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Petrone et al. (2002) studied this question.

synapsesocial.com/papers/69dd75f580eea7d3f699cdfa https://doi.org/10.1002/art.510

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates improved saliva and tear production from cevimeline in Sjögren's syndrome, indicating its efficacy for severe dryness.

A double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

Key Points

Implication

Abstract

Discussion

Cite This Study

A double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading